Literature DB >> 16933236

Bone mineral density before and after OLT: long-term follow-up and predictive factors.

Maureen M J Guichelaar1, Rebecca Kendall, Michael Malinchoc, J Eileen Hay.   

Abstract

Fracturing after liver transplantation (OLT) occurs due to the combination of preexisting low bone mineral density (BMD) and early posttransplant bone loss, the risk factors for which are poorly defined. The prevalence and predictive factors for hepatic osteopenia and osteoporosis, posttransplant bone loss, and subsequent bone gain were studied by the long-term posttransplant follow-up of 360 consecutive adult patients with end-stage primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). Only 20% of patients with advanced PBC or PSC have normal bone mass. Risk factors for low spinal BMD are low body mass index, older age, postmenopausal status, muscle wasting, high alkaline phosphatase and low serum albumin. A high rate of spinal bone loss occurred in the first 4 posttransplant months (annual rate of 16%) especially in those with younger age, PSC, higher pretransplant bone density, no inflammatory bowel disease, shorter duration of liver disease, current smoking, and ongoing cholestasis at 4 months. Factors favoring spinal bone gain from 4 to 24 months after transplantation were lower baseline and/or 4-month bone density, premenopausal status, lower cumulative glucocorticoids, no ongoing cholestasis, and higher levels of vitamin D and parathyroid hormone. Bone mass therefore improves most in patients with lowest pretransplant BMD who undergo successful transplantation with normal hepatic function and improved gonadal and nutritional status. Patients transplanted most recently have improved bone mass before OLT, and although bone loss still occurs early after OLT, these patients also have a greater recovery in BMD over the years following OLT.

Entities:  

Mesh:

Year:  2006        PMID: 16933236     DOI: 10.1002/lt.20874

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  49 in total

Review 1.  Primary sclerosing cholangitis: is any treatment worthwhile?

Authors:  Ashley Barnabas; Roger W Chapman
Journal:  Curr Gastroenterol Rep       Date:  2012-02

Review 2.  Osteoporosis across chronic liver disease.

Authors:  M Guarino; I Loperto; S Camera; V Cossiga; C Di Somma; A Colao; N Caporaso; F Morisco
Journal:  Osteoporos Int       Date:  2016-02-04       Impact factor: 4.507

Review 3.  Orthotopic liver transplantation and what to do during follow-up: recommendations for the practitioner.

Authors:  Daniel Benten; Katharina Staufer; Martina Sterneck
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-11-25

4.  Safety and Efficacy of Budesonide for Liver Transplant Immune Suppression: Results of a Pilot Phase 2a Trial.

Authors:  Khurram Bari; Shimul A Shah; Tiffany E Kaiser; Robert M Cohen; Nadeem Anwar; David Kleesattel; Kenneth E Sherman
Journal:  Liver Transpl       Date:  2020-08-19       Impact factor: 5.799

5.  Bone Density in Children With Chronic Liver Disease Correlates With Growth and Cholestasis.

Authors:  Kathleen M Loomes; Cathie Spino; Nathan P Goodrich; Thomas N Hangartner; Amanda E Marker; James E Heubi; Binita M Kamath; Benjamin L Shneider; Philip Rosenthal; Paula M Hertel; Saul J Karpen; Jean P Molleston; Karen F Murray; Kathleen B Schwarz; Robert H Squires; Jeffrey Teckman; Yumirle P Turmelle; Estella M Alonso; Averell H Sherker; John C Magee; Ronald J Sokol
Journal:  Hepatology       Date:  2018-12-27       Impact factor: 17.425

Review 6.  Vitamin D in organ transplantation.

Authors:  E M Stein; E Shane
Journal:  Osteoporos Int       Date:  2011-01-05       Impact factor: 4.507

Review 7.  Cholestasis and metabolic bone disease - a clinical review.

Authors:  Rudolf W Gasser
Journal:  Wien Med Wochenschr       Date:  2008

Review 8.  Primary sclerosing cholangitis: diagnosis, prognosis, and management.

Authors:  Siddharth Singh; Jayant A Talwalkar
Journal:  Clin Gastroenterol Hepatol       Date:  2013-02-27       Impact factor: 11.382

Review 9.  EASL Clinical Practice Guidelines on nutrition in chronic liver disease.

Authors: 
Journal:  J Hepatol       Date:  2018-08-23       Impact factor: 25.083

Review 10.  Current understanding of osteoporosis associated with liver disease.

Authors:  Inaam A Nakchbandi; Schalk W van der Merwe
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-11       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.